

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Flodgaard et al.

Serial No.: TBA

Group Art Unit: TBA

Filed: April 27, 2000

Examiner: TBA

For: Inhibition Of Bradykinn Release

**VERIFIED STATEMENT UNDER 37 CFR 1.821(f)**

Assistant Commissioner for Patents  
Washington, DC 20231


Sir:

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR § 1.821(c) and (e), respectively, are the same.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issue thereon.

Respectfully submitted,

Date: April 27, 2000

  
Cheryl H. Agis, Reg. No. 34,086  
Outside Counsel for Novo Nordisk  
of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123

002240-4969560